CalciMedica Secures $32.5M Credit Facility to Advance CRAC Channel Inhibitor Development
核心洞察
CalciMedica has secured a $32.5M credit facility from Avenue Venture Opportunities Fund (搜索), with an initial $10M tranche extending cash runway into mid-2026.
The company is advancing development of Auxora, their lead CRAC channel (搜索) inhibitor, with Phase 2 trial data in acute kidney injury (搜索) expected in 2025.
The financing provides strategic flexibility for CalciMedica's clinical programs, including preparations for Phase 3 trials in acute pancreatitis (搜索).
CalciMedica Inc. (Nasdaq: CALC) has secured a credit facility of up to $32.5 million from Avenue Venture Opportunities Fund (搜索) II, L.P., strengthening its financial position to advance novel calcium release-activated calcium (CRAC) channel inhibition therapies. The agreement includes an immediate $10 million funding tranche, extending the company's operational runway into mid-2026.
Strategic Financial Terms
The 3.5-year credit agreement provides significant flexibility with no minimum cash requirements or financial covenants. Beyond the initial $10 million, CalciMedica can access additional tranches totaling $22.5 million upon achieving specific milestones.
Advancing Clinical Development Programs
The funding comes at a crucial time as CalciMedica prepares for several significant clinical milestones. The company's lead candidate, Auxora, is currently being evaluated in multiple clinical trials targeting inflammatory and immunologic conditions.
"This credit agreement provides CalciMedica with additional flexibility as we prepare for multiple critical milestones throughout 2025," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. "The facility extends our cash runway to the middle of 2026, providing us ample runway beyond the KOURAGE readout based on our current enrollment projections."
Key Clinical Programs and Timelines
The company is conducting several clinical trials evaluating Auxora across different indications:
- KOURAGE trial: A Phase 2 study in patients with acute kidney injury and acute hypoxemic respiratory failure, with data expected in 2025
- CRSPA trial: An ongoing Phase 1/2 study in pediatric patients with asparaginase-induced pancreatic toxicity
- Preparations for Phase 3 program discussions with FDA regarding acute pancreatitis indication
Therapeutic Approach and Market Potential
CalciMedica's proprietary CRAC channel (搜索) inhibition technology represents a novel approach to treating inflammatory and immunologic diseases. The company's focus on modulating immune response and protecting against tissue cell injury addresses conditions with significant unmet medical needs.
Chad Norman, Senior Portfolio Manager of Avenue Venture Opportunities Fund (搜索), expressed confidence in the investment: "We appreciate the potential of its lead pipeline candidate, Auxora, to treat acute inflammatory and immunologic diseases and look forward to its continued progress in clinical trials."